Mountain View, California, USA – April 23, 2026

RenovoRx announced that a pharmacokinetic (PK) and pharmacodynamic (PD) data abstract supporting its TAMP™ therapy platform has been accepted for presentation at the 2026 ASCO Annual Meeting, marking a significant milestone in the advancement of its targeted oncology drug-delivery approach. The abstract is based on a sub-study of the ongoing Phase III TIGeR-PaC clinical trial, evaluating intra-arterial delivery of gemcitabine for patients with locally advanced pancreatic cancer, and highlights the platform’s potential to increase local drug potency while reducing systemic toxicity and side effects associated with chemotherapy.

PK/PD Data Demonstrates Enhanced Drug Targeting and Reduced Toxicity

The accepted abstract explores how intra-arterial gemcitabine delivery via RenovoCath®, enabled by the TAMP™ platform, may significantly alter drug distribution compared to traditional intravenous chemotherapy. The findings indicate that this approach can increase localized drug concentration at the tumor site while reducing systemic exposure, a critical factor in improving treatment tolerability and minimizing adverse effects.

Additionally, the study evaluates the relationship between drug metabolite levels and CA 19-9, a key biomarker used to assess chemotherapy response in pancreatic cancer patients, providing further insight into treatment efficacy and pharmacologic activity. This dual focus on pharmacokinetics and pharmacodynamics reinforces the platform’s potential to optimize therapeutic outcomes through precision drug delivery.

The ability to target tumors more effectively while limiting systemic toxicity represents a major advancement in oncology, particularly for aggressive cancers such as pancreatic cancer, where treatment options remain limited.

Advertisement

cGxPJobs Banner

TAMP Platform Enables Precision Oncology Innovation

RenovoRx’s proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform is designed to deliver therapeutic agents directly through the arterial wall near tumor sites, allowing for localized drug perfusion and enhanced tumor exposure. This approach contrasts with conventional systemic delivery methods, which often result in widespread drug distribution and increased toxicity.

The platform is supported by RenovoCath®, an FDA-cleared drug-delivery device, which facilitates temporary vessel occlusion and precise infusion of chemotherapeutic agents. Together, these technologies form a drug-device combination platform aimed at transforming the delivery of oncology therapies.

By enabling higher local drug concentrations and improved safety profiles, the TAMP™ platform aligns with the growing emphasis on precision medicine and targeted therapy in oncology, offering a potential pathway to more effective and patient-friendly cancer treatments.

Phase III TIGeR-PaC Trial and Future Clinical Impact

The PK/PD sub-study is part of the ongoing Phase III TIGeR-PaC clinical trial, which compares intra-arterial gemcitabine delivery versus standard intravenous administration in patients with locally advanced pancreatic cancer. The study is conducted under a U.S. Investigational New Drug (IND) application, highlighting its regulatory significance and potential for future approval.

The acceptance of this abstract at ASCO, one of the world’s leading oncology conferences, underscores the scientific credibility and clinical relevance of RenovoRx’s research. The data will be presented to a global audience of oncology experts, further validating the potential of targeted drug delivery to improve clinical outcomes.

With additional clinical data expected, RenovoRx aims to advance its drug-device combination therapy toward regulatory approval, potentially offering a new standard of care for pancreatic cancer treatment. The continued development of the TAMP™ platform reflects a broader industry shift toward innovative delivery technologies that enhance efficacy while reducing toxicity, ultimately improving patient outcomes.

Source: RenovoRx press release